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Sudden death in healthy athletes is uncommon but, when 
it occurs, the primary mechanism is cardiovascular. The 
major cause of sudden death in the young athlete is 
hypertrophic cardiomyopathy or related conditions 
characterized by left ventricular hypertrophy, aortic 
rupture due to cystic medial necrosis and congenital 
coronary artery abnormalities. In the middle-aged or 
older athlete, coronary artery disease is the most sig•
nificant cause of sudden death. 
Noninvasive screening procedures are currently 
available that can detect most subjects at risk of sudden 
death. However, although some potentially lethal dis•
eases can be excluded by a relatively simple screening 
program, other diseases require expensive procedures, 
such as echocardiography and exercise electrocardio•
graphic stress testing. This means that the sensitivity of 
detecting diseases leading to sudden death increases in 
Sudden death can occasionally strike the competitive or 
recreational athlete. Such an individual is often young; by 
definition he or she is in apparent excellent health. The 
catastrophe, therefore, is totally unexpected and all the more 
tragic and alarming. 
As described by the preceding review of the causes of 
sudden death in young competitive athletes (1), the vast 
majority of these athletes had underlying cardiovascular dis•
ease that could have been responsible for their demise. The 
most common cause of sudden death in this group was 
hypertrophic cardiomyopathy. Other causes were idiopathic 
hypertrophy of the left ventricle (which may represent a 
variant of hypertrophic cardiomyopathy), aortic rupture due 
to cystic medial necrosis, congenital coronary artery ab•
normalities and atherosclerotic coronary artery disease (Ta•
ble I). Other reported series of middle-aged and older ath•
letes who died suddenly (2,3) suggest that coronary artery 
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proportion to the financial resources that can be applied 
to the screening program. Thus, when a screening pro•
gram designed to identify all cardiac diseases that have 
the potential to cause sudden death is planned by a com•
munity, school or nonprofessional athletic team, the costs 
will almost undoubtedly be considered prohibitive. The 
practicality of applying a community- or school-initiated 
screening program can be questioned because of the very 
low incidence of sudden unexpected death in young healthy 
individuals. It is therefore likely that comprehensive 
screening programs will be confined to individuals or 
organizations with adequate financial resources. Less 
expensive, limited screening can be undertaken by in•
dividuals or groups to identify some subjects at risk of 
sudden death during athletic competition. 
(J Am Coil CardioI1986;7:220-30) 
disease is far and away the most common cause of sudden 
unexpected death in this age group. 
The fact that most young and, probably, older athletes 
who die suddenly during or shortly after intense physical 
exertion die from covert cardiac disease leads to two vital 
questions: I) are there noninvasive tests that can effectively 
detect the most common causes of sudden cardiac death in 
athletes, and 2) if such tests are available, are they eco•
nomical enough to utilize as screening procedures? The 
following discussion deals with these issues. It does not 
attempt, however, to consider the screening of other clin•
ically important cardiovascular disorders that do not seem 
to be common causes of sudden death during athletic com•
petition (such as systemic hypertension), nor does it consider 
potentially lethal cerebrovascular disorders (such as berry 
aneurysms). 
Hypertrophic Cardiomyopathy 
Physical examination. The sine qua non of hyper•
trophic cardiomyopathy is a left ventricle that is nondilated 
and hypertrophied (4-6). Figure I displays the characteristic 
auscultatory findings and carotid pulse contour of a patient 
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Table 1. Cause, of Sudden Death in Young Athlete, (:535 
years old) 
Most common causes 
Hypertrophic cardiomyopathy 
Idiopathic left ventricular hypertrophy* 
Aortic rupture (due to "cystic medial necrosis") 
Coronary artery disease 
Congenital coronary abnormalities 
Less common causes 
Valvular aortic stenosis 
Prolonged QT syndrome 
Primary cardiac electrophysiologic abnormalitie, 
Cardiac sarCOidosis 
Myocarditis 
'May be a van ant of hypertrophIC (ardlOmyopathy 
who has hypertrophic cardiomyopathy with assocJated ob•
struction to left ventricular outflow. The obstruction is dy•
namic; it is absent in very early systole and can be altered 
by interventions such as the Val salva maneuver or changes 
in position such as standing or squatting (7), The dynamic 
nature of the obstruction is responsible for the characteristic 
rapid upstroke of the carotid pulse (which excludes fixed 
valvular or subvalvular aortic stenosis) and for the cardiac 
murmur that changes in intensity with such interventions. 
These findings are highly specific in that, when they are 
Figure 1. Phonocardiogram and carotid pulse tracmg obtamed 
from a patient with obstructive hypertrophic cardiomyopathy Note 
the characteristic ",pike and dome" configuration of the carotid 
pulse contour. ECG = electrocardIOgram: 4LlCS = fourth left 
intercostal space. 
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present, the diagnosIs of hypertrophic cardiomyopathy is 
unequivocally established. However, although a substantial 
number of these patients have such classical findings under 
rest conditions, the majority do not because they have either 
no or minimal ba,al obstruction to left ventricular outflow 
(8,9). Thus, the sensitivity of the physical examination in 
this regard is low. 
The chest roentgenogram may be useful in detecting pa•
tient~ with hypertrophic cardiomyopathy because cardiac 
enlargement is often present (10). As with the physical 
examination, however, the majority of patients have either 
no cardiomegaly or very subtle abnormalities that may re•
main undetected in large screening programs. 
Echocardiography. In contrast, echocardiography is 
relatively sensitive and specific in detecting hypertrophic 
cardIOmyopathy. The finding of a hypertrophied nondilated 
left ventricle in the absence of other diseases that might 
produce this abnormality (for example, systemic hyperten•
sIOn or valvular aortic stenosis) strongly suggests the di•
agnosis of hypertrophic cardiomyopathy (4,11). The diag•
no,is is virtually established when marked systolic anterior 
motion of the mitral valve with mitral-septal contact is pres•
ent (II), a finding reflecting obstruction to left ventricular 
outflow. 
There are certain limitations, however, to the use of 
echocardiography in diagnosing hypertrophic cardio•
myopathy ill athletes. First, the absence of systolic anterior 
motion of the mitral valve does not exclude the diagnosis 
because the large majority of patients with hypertrophic 
cardiomyopathy do not have systolic anterior motion. Sec•
ond, the anterior basal portion of the ventricular septum is 
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usually hypertrophied to a greater extent than is the posterior 
left ventricular free wall-hence, the finding of asymmetric 
septal hypertrophy on M-mode echocardiographic study (Fig. 
2). However, other cardiac or systemic conditions may re•
sult in an asymmetric pattern of left ventricular hypertrophy. 
Furthermore, in patients with hypertrophic cardiomyopathy, 
maximal wall thickening is not always located in the anterior 
septum, but may sometimes be identified in the posterior 
portion of the septum or anterolateral left ventricular free 
wall, or be confined to the apical portions of the ventricle. 
Occasionally such left ventricular hypertrophy will be pres•
ent even when the anterior septum is of normal thickness. 
In such instances, the M-mode study results may be normal 
and hypertrophic cardiomyopathy will be detected only with 
two-dimensional echocardiography (5,6). Third, some nor•
mal athletes have septal and posterior wall thicknesses that 
exceed the upper limits of normal (although these thick•
nesses rarely exceed 15 mm) (12-17). In addition, echo•
cardiographic studies of a quality sufficient to definitively 
establish ventricular septal borders cannot always be obtained. 
Finally, there is a gray area of increased septal thickness 
that, although raising the suspicion of hypertrophic cardio•
myopathy, is not abnormal enough to establish the diagnosis 
unequivocally. For example, an increased ventricular septal 
thickness of 13 to 14 mm in an athlete (> 12 mm being 
abnormal in most adults) might be a manifestation of either 
a normal "athletic heart" or a heart with hypertrophic car•
diomyopathy. When such a borderline echocardiogram is 
Figure 2. M-mode echocardiogram demonstrating the classic 
findings of nonobstructive hypertrophic cardiomyopathy. The ven•
tricular septum (YS) is markedly thickened with respect to the 
posterior left ventricular wall (PW), which is of normal thickness. 
MY = mitral valve. 
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obtained, additional information is necessary. In particular, 
two-dimensional echocardiographic study may detect other 
areas of the left ventricle with more marked hypertrophy 
that cannot be imaged with conventional M-mode echo•
cardiography (5,6). Echocardiographic studies in relatives 
can also be of value in this circumstance. Because hyper•
trophic cardiomyopathy is often transmitted as an autosomal 
dominant trait (8,9), the likelihood that slightly increased 
ventricular wall thicknesses in an athlete represents hyper•
trophic cardiomyopathy increases if its morphologic expres•
sion can be identified in the athlete's parents or siblings. 
Electrocardiography. Electrocardiographic studies in 
patients with hypertrophic cardiomyopathy have revealed 
that approximately 90% of such individuals (I8) and more 
than 90% of those who die suddenly (19,20) have an ab•
normal electrocardiogram. The patterns are quite diverse, 
and none is entirely specific for the disease. However, a 
normal electrocardiogram in an athlete would indicate a low 
probability that hypertrophic cardiomyopathy is present and 
a low risk for sudden death if it is. 
Screening studies. Table 2 summarizes the relative power 
of screening studies in detecting hypertrophic cardio•
myopathy. Combined M-mode and two-dimensional echo•
cardiography provide the most sensitive and predictive in•
formation; however, the cost of these tests is high and, as 
discussed later, probably precludes their use in community•
based screening programs. The electrocardiogram yields a 
considerable number of nonspecific "abnormalities" that 
are not predictive of cardiac disease; however, it is suffi•
ciently sensitive in detecting hypertrophic cardiomyopathy 
to make it an important screening study. particularly when 
cost factors must be considered. It is unlikely that many 
additional patients with hypertrophic cardiomyopathy would 
be detected by the concomitant use of chest roentgenograms 
and cardiac auscultation. 
Table 2 also lists the possible screening benefits to be 
derived from the patient's history. The value of including 
a history to detect occult, potentially fatal, cardiac disease 
in "healthy" asymptomatic athletes is perhaps not as great 
as might be expected. A history of occasional exertional 
dyspnea, light-headedness or nonspecific chest discomfort 
may be of little value in athletes, who often routinely drive 
themselves to the point of physical exhaustion. The only 
historical information that should unequivocally alert the 
physician to serious cardiac disease is a history of syncope 
or a family history of hypertrophic cardiomyopathy or of 
premature sudden death ( <40 years of age) in a first degree 
or other close relative. A history of premature sudden death 
in family members is helpful in alerting the physician that 
hypertrophic cardiomyopathy must be considered. How•
ever, although hypertrophic cardiomyopathy may assume a 
particularly malignant clinical course in certain families (21), 
such families are uncommon and such a history will be 
obtained in very few athletes with unsuspected hypertrophic 
JACC Vol. 7. No.1 
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Table 2. Major Causes of Sudden Death in Athletes and Potential Efficacy of Screening Studies 
Causes 
Hypertrophic 
cardiomyopathy 
Cystic medial 
necrosis 
CAD/congenital 
coronary 
abnormahties 
Aortic valve 
stenosIs 
Screening 
Procedures 
History* 
Chest X-ray film 
AuscultatIOn 
Echocardiogram 
12 lead ECG 
History 
Chest X-ray film 
Auscultation 
Echocardiogram 
12 lead ECG 
History 
Chest X-ray film 
Auscultation 
12 lead ECG 
Exercise ECG 
RadlOnuchde studies 
History 
Chest X-ray film 
Auscultation 
12 lead ECG 
Echocardiogram 
Predictive 
Sensillvity Value 
Poor Poor 
Fair Poor 
Fair Excellent 
Excellent Excellentll 
Goodt Poor 
Poor Poor 
Fair Excellent 
Poor Fair 
Excellent Excellent 
Poor Poor 
Poor Fair** 
Poor Poor 
Fair-good Poort 
Excellent Poort 
Poor Poor 
Excellent Good§ 
Fair Poor 
Poor Poor 
* Specifically , a history of syncope or sudden premature death in a close family member tBoth in making 
the diagnosis of hypertrophic cardiomyopathy and in identifying pallents at risk of sudden death. tOf increasing 
value in subjects older than 40 years of age when the prevalence of coronary artery disease increases; however, 
most abnormal responses will still be falsely positive. §The predlcllve value of auscultation depends on intensity 
of murmur; the high prevalence of softer innocent murmurs will necessitate a more sophisticated and expensive 
evaluation m many individuals. IIPredlclive value IS cntically dependent on the magnitude of ventricular septal 
thickness (septal thickness >20 mm would be highly indlcallve of hypertrophic cardiomyopathy; septal thickness 
of 13 to 14 mm, as an isolated clinical finding, would provide only suggestive evidence of disease). **Only 
if coronary calcifications are detected by fluoroscopy; poor If fluoroscopy is not carried out. CAD = coronary 
artery disease; ECG = electrocardiogram. The rating system is based on the followmg sequence: excellent> 
good > fair > poor. 
cardiomyopathy. A history of premature sudden death in 
family members is not specific for hypertrophic cardio•
myopathy but may suggest other diagnoses to be evaluated. 
For example, because sudden death occurs in families with 
the rare prolonged QT syndrome (22-24), the possibility 
that this syndrome is present should also be explored. 
Aortic Rupture Due to Cystic 
Medial Necrosis 
Chest X-ray film. Figure 3 demonstrates the character•
istic chest roentgenogram of a patient with a dilated aortic 
root due to cystic medial necrosis. The ascending aorta is 
prominent, raising the suspicion of aneurysmal dilation. 
Once this abnormality is recognized, additional studies must 
be undertaken, including M-mode (Fig. 4) and two-dimen•
sional echocardiography and, possibly, aortic root contrast 
angiography. However, the difficulty with relying on the 
chest X-ray study to detect occult cystic medial necrosis is 
that a large portion of the proximal aorta lies within the 
cardiac silhouette, and it is not uncommon for there to be 
marked dilation of the root without extension of the dilation 
into the ascending aorta. Under these conditions, the chest 
X-ray film would not demonstrate aortic root dilation (Fig. 
SA and B). 
Physical examination. Although auscultation may be 
of value in the diagnosis of aortic dilation, its sensitivity is 
probably low. The dilated aortic root may produce an early 
ejection sound and, once the root is sufficiently dilated, 
aortic regurgitation occurs. An unexplained aortic regur•
gitation murmur, particularly when heard loudest along the 
right sternal border, should suggest aortic root dilation (the 
murmur of rheumatic aortic regurgitation, or that due to a 
bicuspid aortic value, is almost invariably loudest along the 
left sternal border). These findings, when present, are use•
ful. However, in many patients cystic medial necrosis of 
the aorta cannot be detected on the basis of the physical 
examination alone. 
Echocardiography. On the other hand, M-mode and, 
particularly, two-dimensional echocardiography are highly 
sensitive in detecting an abnormally dilated aortic root (Fig. 
4). Although echocardiography is the best noninvasive pro-
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Figure 3. Typical chest X-ray film of a patIent wIth cystIc medial 
necrosis of the aorta. showing a prominently dilated root and 
ascending aorta and enlarged left ventricle. 
cedure for detecting aortic root dilation (Table 2), its cost 
efficiency is a prominent consideration. 
Coronary Artery Disease 
Electrocardiographic stress test. The electrocardio•
graphic exercise test is potentially the most important screening 
test for detecting occult coronary artery disease in asymp•
tomatic athletes. However, its low predictive value in 
asymptomatic subjects (who have a low pretest likelihood 
of disease) emphasizes the limits of reliability of less than 
perfect diagnostic tests (25-27), especially when applied to 
subjects with a low probability of coronary disease (such 
as athletes < 30 years of age). This concept, in fact. has 
been shown to be directly relevant to young athletes. Thus. 
in a study (28) in which electrocardiographic exercise stress 
testing was conducted in a group of 75 young asymptomatic 
athletes with no clinical evidence of coronary artery disease. 
9% had 1 mm or greater ST segment depression provoked 
by exercise. Although the prevalence of silent coronary 
artery disease in asymptomatic individuals 35 to 55 years 
of age is higher. it is still low enough that a high percent 
of false positive tests can be anticipated (27). 
Screening studies. The dilemma in the use of exercise 
testing in large scale screening programs. even for middle-
lACC Vol 7, No I 
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aged or older asymptomatic athletes. is exemplified by the 
findings of the Seattle Heart Watch Study (29,30). Among 
more than 2.000 men initially free of heart disease. most 
of whom were 35 to 55 years of age, the annual incidence 
of sudden cardiac death was only about 0.05%. Maximal 
exercise testing and risk factor analysis (positive family 
history, smoking, systemic hypertension and hypercholes•
terolemia) identified I % of the population as a group with 
an 18 times greater risk than that of the remaining subjects 
either of developing angina or myocardial infarction or of 
dying (29). If it is assumed that a subgroup at an 18 times 
greater risk of sudden death can, in fact, be identified by 
such means. it would require 10.000 asymptomatic subjects, 
with an annual mortality rate of 0.05%, to undergo screening 
studies to identify the 100 men (I % ) who comprise this high 
risk group. Of these 100 men. only 1 will be destined to 
die. Ironically. even if this massive screening were carried 
out and a high risk group identified. the much larger "low 
risk" group, containing 9.900 subjects. would contain 4 
(80%) of the 5 subjects destined to die, and nOlle of these 
4 individuals would have been identified by screening stud•
ies (Fig. 6). 
Radionuclide techniques. Although the sensitivity and 
specificity for detecting coronary artery disease are higher 
using radionuclide techniques during stress testing, these 
procedures still yield a large percent of false positive results 
when employed in an asymptomatic population (27). They 
are also expensive if one is considering their use in routine 
screening programs. Thus. there are major problems inher-
Figure 4. M-mode echocardiogram demonstrating a dilated aortic 
root (Ao) in a patIent with cystic medial necrosis of the aorta. The 
aortic root measures 50 mm; upper limit of normal is about 30 
mm. LA = left atrium; RVOT = right ventricular outflow tract. 
lACC Vol 7. No I 
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ent in existing screening techniques for detecting underlying 
coronary artery disease in asymptomatic athletes. 
Congenital Coronary Artery Abnormalities 
Congenital abnormalities of the coronary arteries may be 
commonly implicated as the cause of sudden death in young 
athletes (1). For example, a left coronary artery that arises 
anomalously from the right coronary cusp makes, at its 
origin, an acute angle with the aorta as it courses leftward 
to assume its usual left ventricular distribution. A similar 
situation exists when the right coronary artery arises from 
the left coronary cusp. It is hypothesized that with exercise 
the aorta dilates, thereby exacerbating the acute angle and 
possibly causing total or near total occlusion. Another pos•
sible congential coronary artery abnormality that may lead 
to sudden death in the young athlete is absence or under•
development of a major coronary artery, presumably leading 
to inadequate myocardial blood flow to a portion of myo•
cardium (1,2). 
Screening studies. The dilemma posed by congenital 
coronary artery anomalies in the athlete is that no infor•
mation is currently available related to the efficacy of screen•
ing studies in identifying these abnormalities. Thus, the 
frequency with which abnormalities occur on the 12 lead 
electrocardiogram or electrocardiographic stress test in sub•
jects with congenital coronary anomalies is unknown. How•
ever, such anomalies should at least be suspected in a young 
athlete who experiences exertional chest pain or syncope. 
In this setting, a 12 lead electrocardiogram, a two-dimen•
sional echocardiogram (to determine whether the left main 
coronary artery is in the correct position) and an exercise 
stress test would constitute a proper noninvasive evaluation. 
The decision as to whether more extensive studies are in•
dicated (such as radionuclide stress testing or even coronary 
Figure 5. Chest X-ray film (A) and aortic 
root angiogram (B) from a patient with cys•
tic medial necrosis of the aorta. A, The 
dilated aortic root lies entirely within the 
cardiac silhouette. The diagnosis would re•
main undetected using only this technique. 
B, The aortic root is massively dilated and 
the sinuses of Valsalva are obliterated. 
angiography) must be individualized and would depend on 
the likelihood that the symptoms have a cardiac basis. 
Valvular Aortic Stenosis 
In the study on sudden death in young athletes previously 
cited (I), none of the 29 deaths were due to valvular aortic 
Figure 6. Practical implications of employing exercise screening 
plus risk factors to identify asymptomatic subjects older than 35 
years of age at risk of sudden death. The overall annual mortality 
rate is 0.05%. A subgroup of 100 individuals can be identified 
with an 18 times greater risk of dying (annual mortality rate 0.77%) 
than the remainder of the population (annual mortality rate 0.043%). 
EXERCISE 
PLUS 
RISK FACTOR 
SCREEN 
NEGATIVE 
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stenosis. Because patients with aortic stenosis may die sud•
denly, one reasonable explanation for the absence of this 
disease in a relatively large series of athletes dying suddenly 
is that aortic stenosis is an easy diagnosis to establish with 
a very simple screening procedure-cardiac auscultation. 
In a healthy individual with a normal cardiac output, the 
absence of a murmur or the presence of only a soft murmur 
excludes the presence of significant aortic stenosis. Hence, 
this disease is uniquely amenable to a screening program. 
Although virtually all patients with aortic stenosis will 
be identified by such screening, there are many healthy 
young people with systolic murmurs whose innocence or 
significance can only be determined by an experienced phy•
sician. After screening, therefore, many such young athletes 
would have to be referred to sUbspecialists for more exten•
sive, and more costly, evaluations. 
Other Abnormalities 
Several other cardiac abnormalities are probably rela•
tively uncommon causes of sudden death in athletes. Never•
theless, it is important to consider these diseases from the 
standpoint of screening. 
Mitral valve prolapse. The propensity of mitral pro•
lapse to cause sudden death has been of major concern, 
mainly because of the high frequency of this abnormality 
in the general population. Although no studies are available 
documenting the prevalence of mitrql valve prolapse in ath•
letes, screening studies (31,32) of apparently healthy young 
women have revealed that approxi'l1ately 5% have auscul•
tatory or echocardiographic evidence of mitral valve pro•
lapse. In addition, serious ventricl!lar arrhythmias, as well 
as sudden death, have rarely been associated with mitral 
valve prolapse (33-35). These findings raise questions as 
to whether this entity should be searched for in athletes and 
whether its presence in an otherwise healthy person indicates 
that competitive sports be avoided. 
Although definitive data are unavailable, there is little 
question that only the very rare patient with mitral valve 
prolapse dies as a result of this abnormality (35). Because 
mitral valve prolapse appears so frequently in otherwise 
healthy persons, its finding in the absence of any serious 
symptomatic ventricular arrhythmias should probably be 
considered benign and not influence the physician's rec•
ommendations concerning participation in athletic activities 
(36). A more conservative approach would be justified in 
the occasional athlete with mitral valve prolapse and sig•
nificant symptoms or symptomatic ventricular arrhythmias. 
Given existing evidence, it appears unnecessary to routinely 
screen for mitral valve prolapse in asymptomatic athletes. 
Wolff-Parkinson-White syndrome. Although patients 
with the Wolff-Parkinson-White pattern on the electrocar•
diogram have been known to die suddenly, it appears that 
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the incidence of sudden death in such subjects is low (37). 
Moreover, several studies (37-39) suggest that those pa•
tients with the Wolff-Parkinson-White syndrome who are 
most susceptible to ventricular fibrillation and sudden death 
are those exhibiting atrial fibrillation with a rapid ventricular 
response. Thus, if the electrocardiographic pattern of Wolff•
Parkinson-White syndrome is detected in the absence of 
clinically apparent arrhythmias, no evidence exists to justify 
proscribing participation in strenuous athletic activities (36). 
~t also does not appear necessary to screen for this abnor•
mality in the asymptomatic athlete. 
Primary cardiac electrical abnormalities. Many pre•
sumably healthy individuals, particularly those who are older 
than 40 years of age, have frequent premature ventricular 
complexes. In the absence of both underlying cardiac dis•
ease and symptomatic consequences of the arrythmia, the 
association of such complexes (or even ventricular tachy•
cardia) with sudden death is extremely rare (36,40-44). 
Thus, although an argument could be made for obtaining 
a standard 12 lead electrocardiogram, it is not necessary to 
employ ambulatory electrocardiographic monitoring to screen 
asymptomatic subjects who want to participate in a stren•
uous athletic program. This procedure is not only expensive, 
but the results would be clinically relevant only (with rare 
exceptions) if serious structural heart disease was also present. 
Implications of Cost-Effectiveness on 
Developing a Strategy to Detect Potentially 
Lethal Cardiovascular Disease in the Athlete 
The feasibility of screeping competitive or recreational 
athletes must be considered on two levels: 1) community•
based screening in which schools or other organizations 
adopt routine screening procedures for members of their 
group who have decided to participate in athletic actiyites, 
and 2) individual-initiated screening in which the prospec•
tive athlete, on the advice of his or her physician, determines 
which screening studies should be undertaken. The com•
munity-based approach is, with the exception of financially 
well endowed professional organizations, almost invariably 
burdened by financial constraints. This also applies to the 
individual-initiated approach, so that the comprehensiveness 
of the screening program will ultimately be closely tailored 
to the subject's financial resources. 
On the basis of informal surveys aided by the American 
Heart Association (Nancy V. Wilson) and the American 
College of Cardiology (David J. Feild), cost estimates for 
the screening studies discussed in this review were approx•
imated. Two types of cost structure were developed: one 
for large volume community-based screening programs, and 
a second for screening studies undertaken for the individual 
athlete in a private physician's office. Although most echo•
cardiographic evaluations now include both M-mode and 
two-dimensional studies, the data we developed fOT echo-
JACC Vol 7. No I 
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cardiographic testing were limited to M-mode studies be•
cause the additional expense of two-dimensional studies 
would be prohibitive in most screening situations. The pre•
cise costs vary considerably among different communities 
and areas of the country and will obviously fluctuate with 
changes in the economy. Thus, the estimates employed in 
the subsequent discussion are intended to describe only in 
a very general way the financial impact of screening pro•
grams for athletes. 
Athletes 35 Years of Age or Younger 
Role of screening prognosis. It would not appear eco•
nomically feasible for a high schooL college or athletic club 
to initiate a screening program that would identify most of 
the cardiovascular problems responsible for sudden death 
in young athletes (Table 3). Thus, each organization must 
determine for itself the type of program it is capable of 
financing. For example, although cardiac auscultation can 
detect all patients with aortic stenosis at low cost, such a 
screening procedure, even if it includes a cardiac history, 
will fail to detect a large number of patients with hyper•
trophic cardiomyopathy, and virtually all patients with cys•
tic medial necrosis, coronary artery disease or congenital 
coronary anomalies. If funds are available to permit a chest 
X-ray to be obtained, many individuals with cystic medial 
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necrosis will be identified as will additional patients with 
hypertrophic cardiomyopathy. This screening program, 
however, will fail to detect most patients with hypertrophic 
cardiomyopathy, many with cystic medial necrosis and all 
with coronary artery abnormalities. If a 12 lead electrocar•
diogram is added to the profile, most patients with hyper•
trophic cardiomyopathy at risk of sudden death will be de•
tected. However, the electrocardiogram will not detect any 
additional patients with cystic medial necrosis and only the 
occasional patient with coronary artery disease or a con•
genital coronary artery abnormality. Echocardiography and 
exercise electrocardiographic stress testing are prohibitively 
expensive for most athletic organizations. However, be•
cause most subjects with hypertrophic cardiomyopathy at 
risk of sudden death will probably be detected by an ab•
normal rest 12 lead electrocardiogram (19,20), and because 
coronary artery disease is so uncommon in high school- or 
college-aged subjects, it is difficult to justify the costs of 
adding echocardiography and exercise electrocardiography 
to a large scale screening program. 
It is unfortunate, given the large number of young people 
participating in athletic programs in any given high school 
or college, that all but the least expensive screening program 
would be beyond the financial resources of most institutions 
or individual families. Under these circumstances, families 
with adequate financial resources might choose to pay for 
additional screening studies to detect the diseases that might 
Table 3. Possible Community-InitIated Screening Strategies for Identifying the Athlete at RIsk 
of Sudden Death 
Screening Battery Cost* 
History, auscultation 25 
HI,tory. auscultation, 25 
chest X-ray film 25 
Total 50 
HistOry, auscultation, 25 
chest X-ray film. 25 
12 lead ECG 25 
Total 75 
Hi,tory. auscultahon. 25 
chest X-ray film. 25 
12 lead ECG, 25 
echocardlOgraphy (M-mode) 100 
Total 175 
History. aw,cultation, 25 
che't X-ray film, 25 
12 lead ECG, 25 
echocardiography (M-mode) 100 
exercise ECG 75 
Total 250 
Will Detect 
All AS. 
25'7< of all HCM. 
some CMN 
All AS. 
30'70 of all HCM. 
many CMN 
All AS. 
most HCM at risk 
of SD 
All AS. 
mmt HCM. 
most CMN 
All AS. 
most HCM. 
most CMN, 
~20% of CAD/CAA 
at w,k of SD 
WIll Miss 
75% of HCM. 
all CAD/CAA. 
Most CMN 
70% of HCM, 
all CAD/CAA, 
many CMN 
Many CMN. 
vIrtually all CAD/CAA 
Virtually all 
CAD/CAA 
~80% of CAD/CAA 
at risk of SD 
*Costs In U. S. dollars are based on estimates of a large scale screening effort. rather than on the prevailing 
rates In a private office or clInic. AS = aortic stenosIS; CAA = coronary artery anomalies; CAD = coronary 
artery disease; CMN = cystic medial necrosIs; ECG = electrocardiogram; HCM = hypertrophic cardio•
myopathy; SD = sudden death. 
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predispose to sudden death. Table 4 outlines the costs and 
results of such studies. Although the decision to undergo 
such screening can be made only by the prospective athlete 
and his family, it must be emphasized that sudden death in 
young competitive athletes is extremely rare, and the like•
lihood that any single "normal" young athlete will be at 
risk of sudden death is extraordinarily low. 
Clinical implications. To place things in perspective, 
we have made some conservative estimations of the practical 
implications of etnploying a preparticipation screenihg ex•
amination to identify young athletes at risk of sudden death. 
We assumed that in young asymptomatic individuals wish•
ing to participate in an athletic program: I) the prevalence 
of congenital heart disease is about 0.5% (45), 2) approx•
imately I % of such asymptomatic subjects have a cardiac 
abnormality that could potentially cause sudden death, and 
3) approximately 10% of individuals with underlying car•
diac disease that could cause sudden death will, indeed, die 
suddenly as a result of athletic competition. On the basis 
of these rough estimates and the assumption that screening 
procedutes could successfully identify all subjects with heart 
disease while producing no false positive results, it can be 
calculated that to identify a group of 1,000 athletes who 
have cardiovascular disease, of whom perhaps only I athlete 
will die, 200,000 competitive athletes will have to be screened 
(Fig. 7). 
Athletes Older Than 35 Years of Age 
Role of screening programs. Although similar consid•
erations apply to middle-aged individuals, the threat of sud•
den death is necessarily of greater concern because of the 
considerably higher prevalence of coronary artery disease 
in such subjects. Although a workable screening program 
including tests to identify underlying coronary artery disease 
would, therefore, be desirable (Table 4), not only would 
0.5% 
1% 
~ATHLETES .-:,,: .. \ WITH DISEASE .:.10.; CAPABLE ......... OF CAUSING SUDDEN 10% DEATH 
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Figure 7. Practical implications of employing screening studies 
to identify asymptomatic subjects younget than 30 years of age at 
risk elf sudden death (see text for details). CHD = coronary heart 
disease. 
the costs be high, but similar methodologic problems would 
exist as suggested for young athletes. For example, the 
prevalence of underlying cardiac disease posing a threat of 
sudden death in a group of 35 to 55 yeat old asymptomatic 
men may be approximately 3% (25,46). This figure might 
double or triple if additional risk factors (such as systemic 
hypertension, hypercholesterolemia or history of smoking) 
are also present. Given this relatively low prevalence of 
disease, there would be major problems in identifying by 
large scale screening studies those asymptomatic middle•
aged individuals who are at risk of sudden death (Fig. 6). 
One last point should be addressed. This relates to the 
individual who comes to the physician seeking advice about 
Table 4. Possible Individual-Initiated Screening Strategies for Identifying the Athlete at Risk of 
Sudden Death 
Cost* 
Athlete ::; 35 years old 
History and auscultation 25 
Chest X-ray film 30 
12 lead ECG 35 
Echocardiography (M-mode) 200 
Total 290 
Athlete >35 years old 
History and auscultation 25 
Chest X-ray film 30 
12 lead ECG 35 
Echocardiography (M-mode) 200 
Exercise ECG 200 
Total 490 
Will Detect 
All AS, 
!nost HCM, 
most CMN 
All AS, 
most HCM, 
most CMN, 
-20% of CAD 
at fisk of SD 
Will MISS 
Virtually all CAD/CAA 
(but prevalence is low in 
young athletes) 
-80% of CAD 
at fisk of SD 
*Costs in U.S. dollars are based on rough estimates of what such studies might cost in a pflvate office or 
clinic. Abbreviations as III Table 3. 
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whether to undergo stress testing, Although such a request 
may reflect only the patient's natural caution or awareness 
of developments in medicine, many persons are motivated 
to see their physician because they have experienced some 
disturbing or puzzling symptoms, This critical information 
may not always be transmitted to the physician; indeed, the 
individual may not be able to formulate verbally the source 
of anxiety concerning his or her physical well-being, There•
fore, we believe that when an individual asks whether 
screening studies should be performed before participating 
in athletics, it is probably wise to proceed with such studies, 
Conclusions 
The considerations presented in this review emphasize 
the dilemmas posed in attempting to establish an econom•
ically feasible and relatively successful large scale screening 
program to identify life-threatening cardiac problems in 
asymptomatic subjects who wish to participate in an athletic 
program, Noninvasive screening studies are available that 
can identify most such problems, but very few persons are 
at risk and comprehensive community-based screening pro•
grams for large groups of athletes are economically im•
practical. More modest programs, however, commensurate 
with the financial resources available, can be undertaken 
that will identify at least some of the athletes at risk, It is 
also possible for an individual with adequate financial re•
sources to undergo a comprehensive (and unavoidably ex•
pensive) noninvasive screening evaluation that can dem•
onstrate whether he or she has a very low risk of sudden 
death (and thus can participate safely) or has an abnormality 
that poses some risk to life, It must be understood, however. 
that a "low risk" designation refers to probability, and can 
never entirely rule out the possibility of sudden death, and 
that a "some risk" designation is also simply a probability 
statement, often indicating that additional testing is neces•
sary to establish more definitively the diagnosis as well as 
its functional implications. 
We thank Imogene Surrey for a"l',tance In the typing of the manu.,cnpt 
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